DO
Regulatory Correspondent
Daniel Okafor
Covers FDA, DEA and state pharmacy boards, warning letters, enforcement and legislation touching peptides.
Beats: Regulatory, Compounding · 28 entries on the wire
PEPTI publishes pharmacy certificates of analysis on quality page
State Medicaid Program to Begin Covering GLP-1 Weight Loss Drugs
Commentary urges platforms to curb peptide promotion on social media
Washington Post Tracks Escalating Fight Over GLP-1 Coverage
MEDVi Swaps PT-141 for Apomorphine in 2026 QUAD Formula
CBS: companies illegally sell unapproved Lilly drug retatrutide online
Third Texas peptide compounder hit with recall, watchdog reports
Forbes questions Wegovy's path into Medicare Part D coverage
Unapproved Peptide Treatments Spread as Safety Concerns Mount
Johns Hopkins examines the compounding problem in peptide therapies
Philippine FDA warns against unauthorized Jansassy peptide skincare serum
Unapproved 'Wolverine' peptide use surges amid RFK Jr. backing
Reuters: Use of Untested 'Wolverine' Peptide Rises, Study Finds
Study Documents Rising Use of Unapproved 'Wolverine' Peptide
USA Today Guides Patients on Vetting Compounded GLP-1 Sellers
Safe Medicines Group Warns of Compounded GLP-1 Crisis
Centric Compounding Recalls Three Injectable Products Over Contamination
Counterfeit retatrutide linked to torn oesophagus, officials warn
Another Texas pharmacy recalls injectable peptides over fatal risk
PEPTI publishes a seven-point checklist for vetting peptide telehealth
PlexusDx ranks 50 compounded tirzepatide providers by true cost
Report: approved peptides rest on limited human research
FDA warns public against unregistered tirzepatide product
Thai FDA seizes peptide products worth over 52 million baht
MedPage Today examines claims behind booming peptide market
FDA advisers back six peptides for compounding list
Peptide therapy's growing popularity raises questions for doctors, patients
Judge trims Eli Lilly conspiracy claims in compounded tirzepatide suit